Do economic evaluations of targeted therapy provide support for decision makers?

Journal of Oncology Practice

Volumn 7, Issue 3 SUPPL., 2011, Pages

  Ferrusi, Ilia L ^a,b,c,d,e   Leighl, Natasha B ^a,b,c,d,e   Kulin, Nathalie A ^a,b,c,d,e   Marshall, Deborah A ^a,b,c,d,e  

^a CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANADA; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DATA EXTRACTION; DECISION SUPPORT SYSTEM; DRUG EFFICACY; EARLY CANCER; ECONOMIC EVALUATION; HEALTH CARE PLANNING; HUMAN; MOLECULARLY TARGETED THERAPY; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINE; SYSTEMATIC REVIEW; UNITED KINGDOM; UNITED STATES; UNIVARIATE ANALYSIS;

EID: 80052759442     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2011.000315     Document Type: Article

References (62)

1. Berger ML, Teutsch S: Cost-effectiveness analysis: From science to application. Med Care 43:49-53, 2005 (suppl 7)
2. Buxton MJ, Drummond MF, Van Hout BA, et al: Modelling in economic evaluation: An unavoidable fact of life. Health Econ 6:217-227, 1997 (Pubitemid 27296586)
3. O'Brien B: Economic evaluation of pharmaceuticals: Frankenstein's monster or vampire of trials? Med Care 34:DS99-DS108, 1996 (suppl 12)
4. Briggs AH, Sculpher MJ, Logan RP, et al: Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age. BMJ 312:1321-1325, 1996 (Pubitemid 26158301)
5. Pauker SG: Coronary artery surgery: The use of decision analysis. Ann Intern Med 85:8-18, 1976
6. Schoenbaum SC, McNeil BJ, Kavet J: The swine-influenza decision. N Engl J Med 295:759-765, 1976
7. Snider DE, Holtgrave DR, Dunet DO: Decision analysis, in Haddix AC, Teutsch SM, Shaffer PA, et al (eds): Prevention Effectiveness. A Guide to Decision Analysis and Economic Evaluation. Oxford University Press, New York, NY, 1996, pp 27-45
8. Weinstein MC, Toy EL, Sandberg EA, et al: Modeling for health care and other policy decisions: Uses, roles, and validity. Value Health 4:348-361, 2001 (Pubitemid 32946233)
9. Mancinelli L, Cronin M, Sadée W: Pharmacogenomics: The promise of personalized medicine. AAPS PharmSci 2:E4, 2000
10. Ferrusi IL, Marshall DA, Kulin NA, et al: Looking back at 10 years of trastuzumab therapy: What is the role of HER2 testing? - A systematic review of health economic analyses. Per Med 6:193-215, 2009
11. Canadian Agency for Drugs and Technologies in Health (CADTH): Guidelines for the Economic Evaluation of Health Technologies: Canada (ed 3). Canadian Association for Drugs and Technologies in Health, Ottawa, Ontario, Canada, 2006
12. National Institute for Health and Clinical Excellence (NICE): Guide to the Methods of Technology Appraisal. National Institute for Health and Clinical Excellence, London, United Kingdom, 2008
13. Academy of Managed Care Pharmacy (AMCP): AMCP Format for Formulary Submissions Version 2.1. Academy of Managed Care Pharmacy, Alexandria, VA, 2005
14. Drummond MF, Sculpher MJ, Torrance GW, et al: Critical assessment of economic evaluation, in Drummond MF, Sculpher MJ, Torrance GW, et al: Methods for the Economic Evaluation of Health Care Programmes (ed 3). Oxford University Press, New York, NY, 2005, pp 27-53
15. Fenwick E, Claxton K, Sculpher M: Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Econ 10:779-787, 2001 (Pubitemid 34041389)
16. Claxton K: Bayesian approaches to the value of information: Implications for the regulation of new pharmaceuticals. Health Econ 8:269-274, 1999
17. Hoffmann-La Roche: Herceptin (trastuzumab) NICE submission: Achieving clinical excellence in the adjuvant treatment of HER-2 positive breast cancer. http://www.nice.org.uk/nicemedia/live/11585/33437/33437.pdf
18. Vernaglia PR, Cunha FM, Correa M, et al: Cost-effectiveness analysis of trastuzumab therapy in patients with early HER-2 positive breast cancer in Brazil. Breast Cancer Res Treat 106:S106, 2007
19. Hillner BE: Clinical and cost-effectiveness implications of adjuvant trastuzumab in HER2+ breast cancer trials. Presented at 2005 San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2005 (abstr 5040)
20. Hornberger J, Kerrigan M, Foutel V: Cost-effectiveness of trastuzumab (Herceptin) for treatment of metastatic breast cancer. Ann Oncol 13:52, 2002
21. Ragaz J, Spinelli JJ: Cost-benefit estimates of adjuvant trastuzumab for early breast cancer. Presented at 2005 San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2005 (abstr 2029)
22. Lopes GD: An evaluation of the societal costs and benefits of adjuvant trastuzumab in the treatment of early HER2neu-positive breast cancer in Singapore. J Clin Oncol 28, 2010 (abstr e16514)
23. Clark O, Paladini L, Clark LG, et al: Trastuzumab on adjuvant breast cancer treatment: Evidence synthesis and health technology evaluation. Value Health 12:A289, 2009 (abstr PCN166)
24. Guiliani G, Ray JA, Urspruch A: Cost-effectiveness analysis of adjuvant therapy with trastuzumab for HER2-positive breast cancer in Italy utilizing follow- up data. Value Health 12:A276, 2009 (abstr PCN102)
25. US Federal Reserve: Foreign exchange rates (weekly). http://www. federalreserve.gov/releases/H10/default.htm
26. US Bureau of Labor Statistics: Consumer price index - all urban consumers, medical care; Series ID: SUUR0000SAM (2011)
27. Skedgel C, Rayson D, Younis T: The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: An analysis based on updated results from the HERA trial. Value Health [epub ahead of print on March 10, 2009]
28. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006 (Pubitemid 43290919)
29. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
30. Blank PR, Schwenkglenks M, Moch H, et al: Human epidermal growth factor receptor 2 expression in early breast cancer patients: A Swiss cost-effectiveness analysis of different predictive assay strategies. Breast Cancer Res Treat 124:497-507, 2010
31. Press MF, Sauter G, Bernstein L, et al: Diagnostic evaluation of HER-2 as a molecular target: An assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11:6598-6607, 2005 (Pubitemid 41339000)
32. Dendukuri N, Khetani K, McIsaac M, et al: Testing for HER2-positive breast cancer: A systematic review and cost-effectiveness analysis. CMAJ 176:1429-1434, 2007 (Pubitemid 46762020)
33. Chen W, Jiang Z, Shao Z, et al: An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer. Value Health 12:S82-S84, 2009
34. Dedes KJ, Szucs TD, Imesch P, et al: Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: A model-based analysis of the HERA and FinHer trial. Ann Oncol 18:1493-1499, 2007 (Pubitemid 47365481)
35. Essers BA, Seferina SC, Tjan-Heijnen VC, et al: Transferability of model-based economic evaluations: The case of trastuzumab for the adjuvant treatment of HER2-positive early breast cancer in the Netherlands. Value Health 13:375-380, 2010
36. Garrison LP Jr, Lubeck D, Lalla D, et al: Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 110:489-498, 2007 (Pubitemid 47106136)
37. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
38. Kurian AW, Thompson RN, Gaw AF, et al: A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol 25:634-641, 2007 (Pubitemid 350002917)
39. Liberato NL, Marchetti M, Barosi G: Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 25:625-633, 2007 (Pubitemid 350002916)
40. Elkin EB, Weinstein MC, Winer EP, et al: HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol 22:854-863, 2004 (Pubitemid 41103597)
41. Millar JA, Millward MJ: Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: A lifetime model. Pharmacoeconomics 25:429-442, 2007 (Pubitemid 46744472)
42. Norum J, Olsen JA, Wist EA, et al: Trastuzumab in adjuvant breast cancer therapy: A model based cost-effectiveness analysis. Acta Oncol 46:153-164, 2007
43. Neyt M, Huybrechts M, Hulstaert F, et al: Trastuzumab in early stage breast cancer: A cost-effectiveness analysis for Belgium. Health Policy 87:146-159, 2008
44. National Institute for Health and Clinical Excellence: Trastuzumab for the Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer. National Institute for Health and Clinical Excellence, London, United Kingdom, 2008
45. Shiroiwa T, Fukuda T, Shimozuma K, et al: The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: Based on 2-year follow-up HERA trial data. Breast Cancer Res Treat 109:559-566, 2008 (Pubitemid 351692065)
46. Smith I, Procter M, Gelber RD, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369:29-36, 2007 (Pubitemid 46039831)
47. Van Vlaenderen I, Canon JL, Cocquyt V, et al: Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities. Acta Clinica Belgica 64:100-112, 2009
48. Lidgren M, Jönsson B, Rehnberg C, et al: Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol 19:487-495, 2008 (Pubitemid 351325669)
49. Garrison LP Jr, Neumann PJ, Erickson P, et al: Using real-world data for coverage and payment decisions: The ISPOR Real-World Data Task Force report. Value Health 10:326-335, 2007 (Pubitemid 47481104)
50. Phillips KA, Liang SY, Van Bebber S, et al: Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value. Curr Opin Mol Ther 10:260-266, 2008 (Pubitemid 351799277)
51. Phillips KA: Closing the evidence gap on the use of emerging testing technologies in clinical practice. JAMA 300:2542-2544, 2008
52. Steinbrook R: Health care and the American Recovery and Reinvestment Act. N Engl J Med 360:1057-1060, 2009
53. Tunis SR, Pearson SD: Coverage options for promising technologies: Medicare's 'coverage with evidence development.' Health Aff (Millwood) 25:1218-1230, 2006 (Pubitemid 44497620)
54. Berry DA, Cronin KA, Plevritis SK, et al: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792, 2005 (Pubitemid 41549890)
55. Poncet B, Bachelot T, Colin C, et al: Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: A cost-effectiveness analysis. Am J Clin Oncol 31:363-368, 2008
56. Dranitsaris G, Norris B, Hanna W, et al: Identifying the optimal testing of HER2 testing in patients with breast cancer: A Canadian economic evaluation. Curr Oncol 10:36-44, 2003 (Pubitemid 36578396)
57. Drummond MF, Sculpher MJ, Torrance GW, et al: Critical assessment of economic evaluation, in Drummond MF, Sculpher MJ, Torrance GW, et al (eds): Methods for the economic evaluation of health care programmes (ed 3). Oxford University Press, New York, NY, 2005, pp 27-53
58. Alban A, Gyldmark M, Pedersen AV, et al: The Danish approach to standards for economic evaluation methodologies. Pharmacoeconomics 12:627-636, 1997 (Pubitemid 27520876)
59. Collège des Économistes de la Santé: French Guidelines for the Economic Evaluation of Health Care Technologies. Collège des Économistes de la Santé, Paris, France, 2004, pp 1-86
60. Graf von der Schulenburg JM, Greiner W, Jost F, et al: German recommendations on health economic evaluation: Third and updated version of the Hanover Consensus. Value Health 11:539-544, 2008 (Pubitemid 352032814)
61. Stout NK, Knudsen AB, Kong CY, et al: Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics 27:533-545, 2009
62. Weinstein MC, O'Brien B, Hornberger J, et al: Principles of good practice of decision analytic modeling in health care evaluation: Report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 6:9-17, 2003 (Pubitemid 36228345)